Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

Group 1 - Indivior PLC has announced the cancellation of its secondary listing on the London Stock Exchange effective July 25, 2025, while maintaining its primary listing on the Nasdaq Stock Market [1] - An FAQ document has been prepared for shareholders regarding the London Delisting, which is accessible on the company's website [2] - Indivior is a global pharmaceutical company focused on developing medicines for opioid use disorder (OUD), aiming to transform OUD into a recognized chronic disease [3][4] Group 2 - The company has a pipeline of product candidates to expand its portfolio of OUD treatments and operates in over 30 countries worldwide [4] - Indivior is headquartered in Richmond, Virginia, and employs over 1,000 individuals globally [4]